Journal Publications

• A Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia
  

  Journal of Clinical Oncology.  Submitted for publication, August 2010.

• Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults with Acute Myeloid Leukemia and Unfavorable Prognostic Factors
  

  Journal of Clinical Oncology. (Journal of Clinical Oncology 2010:28:4:549-555)

• Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma
  

  Blood. (Blood 2010:115:3:475)

• Safety and Efficacy of Romiplostim in Patient with Lower-risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia
  

  Journal of Clinical Oncology. (Journal of Clinical Oncology 2010:28:3:437-444)

• Improved Quality of Life for Romiplostim-Treated Patients with Chronic Immune Thormbocytopenic Purpura: Results from Two Randomized, Placebo-Controlled Trials
  

  British Journal of Haematology, 2009 (Br J Haematol 2009:144(3):409-415)

• Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  Journal of Clinical Oncology, 2009 (JCO 2009:27:11:1850-1856)

• Recent Advances in Low- and Intermediate-1--Risk Myelodysplastic Syndrome: Developing a Consensus for Optimal Therapy
  

  Clinical Advances in Hematology & Oncology, 2008 (Clin Adv Hem Onc 2008:6(12):1-16)

• Phase 2, Single-arm, Trial to Evaluate the Effectiveness of Darbopoetin alfa for Correcting Anaemia in Patients with Myelodysplastic Syndromes
  

  British Journal of Haematology, 2008 (Br J Haematol 2008:142(3):379-393)

• Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with Chronic ITP
  

  Blood, 2009 (Blood 2009:113:2151-2171)

• Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: a Double-blind Randomised Controlled Trial
  

  Lancet, Feb. 2, 2008 (Lancet 2008:371:395-403)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes
  

  Cancer, March 15, 2007 (Cancer 2007:109(9):1705-1714)

• AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
  

  New England Journal of Medicine, October 19, 2006 (N Engl J Med 2006:355:1672-1681)

• Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period
  

  Clinical and Applied Thrombosis/Hemostasis, October 1, 2006. (Clin Appl Thromb Hemost. 2006 :12(4):389-396)

• Low-Dose Vitamin K to Augment Anticoagulation Control
  

  Pharmacotherapy, October 2005.(Pharmacotherapy 2005:25(12):1746-1751)

• Initial Management of Immune Thrombocytopenic Purpura in Adults: A Randomized Controlled Trial Comparing Intermittent anti-D with Routine Care
  

  American Journal of Hematology, November 2003 (Am J Hematol 2003:74(3):161-169)

Abstracts

• Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry
  

  Blood 2009:114:#4834

• Outpatient Treatment with Clofarabine in Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia
  

  Blood 2009:114:#4162

• Clorfarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities
  

  Blood 2009:114:#4155

• Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who > or = 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors
  

  Blood 2009:114:#2083

• Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
  

  Blood 2009:114:#1770

• Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors
  

  Blood 2009:114:#2061

• An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2009:114:#2765

• Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP)
  

  Blood 2009:114:#1770

• Updated Remission Duration and Survival Results of Single-agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia Unlikely to Benefit From Standard Induction Chemotherapy Due to Unfavorable Baseline Risk Factor(s)
  

  J Clin Oncol 2009:27:15s:#7062

• Results of a Phase II Study of Bortezomib in Patients with Relapsed or refractory Indolent Lymphoma
  

  Blood 2008:112:#1572

• Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia
  

    Blood 2008:112:#327

• Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy
  

  Blood 2008:112:#558

• Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP)
  

  Blood 2008:112:#4707

• Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with ITP
  

  Blood, Nov. 3, 2008. Accepted for publication

• Rapid Onset of Effectiveness with Three Alternative Azacitidine (AZA) Dosing Regimens in Patients with Myelodysplastic Syndromes (MDS)
  

  Haematologica 2008:93(sl):93:#0232

• Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy
  

  J Clin Oncol 2008:26:#7025(May 20 suppl)

• Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2007:110:11:#819

• Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
  

  Blood 2007:110:11:#1300

• Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531
  

  lood 2007:110:11:#1314

• Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients with Low Risk Myelodysplastic Syndrome (MDS): Update on Extended Treatment
  

  Blood 2007:110:11:#250

• Thrombocytopenia in MDS: Incidence and Impact
  

  Supportive Care Cancer 2007:15:651-797:#P-148

• Tolerability and Hematologic Improvement Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  J Clin Oncol 2007: 25:18S:#7083(June 20 Supplement)

• Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study
  

  Supportive Care Cancer 2007:15:651-797;#P-150

• The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks
  

  J Supp Oncology 2007:5:4:#14(Suppl.2 April 2007)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome
  

  J Supp Oncology 2007:5:4: #74(Suppl.2 April 2007)

• Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-week Update
  

  J Supp Oncology 2007:5:4:#78(Suppl.2 April 2007)

• Baseline Predictors of Response to Treatment with Darbepoeitin-alpha (DA) in Anemic Patients with Low-risk Myelodysplastic Syndrome (MDS)
  

  J Clinical Oncol 2007: 25:18S:#7081(June 20 Supplement)

• Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study
  

  J Clin Oncol 2007:25:18S:#7032(June 20 Supplement)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes
  

  Cancer 2007:109(9):1705-14

• Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-blind, Placebo-controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy
  
• The Clinical and Direct Medical Cost Burden of Splenectomy Among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP)
  

  Blood 2006:108:11:#5536

• Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use
  

  Blood 2006:108:11:#3295

• Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenia Purpura: 48-week Update
  

  Blood 2006:108:11:#476

• Darbopoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Interim Results After 27/28 Weeks
  

  J Clin Oncol 2006: 24:18S:#6564(June 20 Supplement)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes (MDS)
  

  Blood 2006:108:11:#2617

• Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  Blood 2006:108:11:#2662

• The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks
  

  Blood 2006:108:#2671

• Darbepoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndromes: Exploratory Analysis of Baseline Predictors of Response
  

  J Clin Oncol 2006: 24:18S:#6579(June 20 Supplement)

• Transfusion Independence Assessed During Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  J Clin Oncol 2006: 24:18S:#6574(June 20 Supplement)

• A Phase 2, Single-Arm, Open-Label Trial to Evaluate the Effectiveness of Darbopoeitin Alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes
  

  Blood 2005:106:11:#2541

• Long-term Dosing of AMG 531 is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura
  

  Blood 2005:106:11:#220

• Azicitidine (Vidaza) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2005:106:11:#2517

Feature Articles

• Sharon Wilks, MD Featured in March 2009 Issue of MD News Magazine
  

  MD News. 2009:2:3:4-6.

• Roger M. Lyons, MD Featured in June 2008 Issue of MD News Magazine
  

  MD News. 2008:1:3:4-9.

Publications & Abstracts

• Publications and Abstracts for Roger M. Lyons, MD, FACP